Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types.

The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong despite a weaker 5 year record.

If the NeXT Personal data has you looking across cancer genomics and related tools, this is a useful moment to scan other potential opportunities using the 41 healthcare AI stocks

With Personalis stock up sharply over the past year and trading only about 11% below the latest analyst price target, the key question is whether recent ASCO data leaves upside on the table or whether markets are already pricing in future growth.

Most Popular Narrative: 10% Undervalued

With Personalis stock closing at $9.79 versus a narrative fair value of $10.86, the current setup hinges on how far its long term margin and growth story can stretch.

Imminent Medicare coverage decisions for at least two cancer indications (expected by year-end) represent a pivotal reimbursement catalyst; once achieved, this unlocks a sizable, recurring revenue stream and allows Personalis to recognize higher-margin reimbursed clinical test revenue, materially improving gross margins and overall profitability.

Curious what revenue ramp, margin shift, and future earnings multiple sit behind that fair value? The widely followed narrative ties them together in a way that may surprise you.

Result: Fair Value of $10.86 (UNDERVALUED)

However, Personalis still faces real pressure if Medicare or other payers delay coverage decisions, or if rivals in MRD testing intensify price and volume competition.

Another View: Personalis stock through a sales multiple lens

While the narrative fair value suggests Personalis stock is about 10% undervalued at $9.79, the current P/S ratio of 15.9x tells a less forgiving story. That compares with 3.7x for the wider US Life Sciences industry, 7.9x for peers, and a 3.4x fair ratio estimate.

This gap implies investors today are paying several times more per dollar of sales than both the sector and closer peers. This raises the risk that any stumble in revenue or margins could hit the share price harder than a simple fair value model might imply. The question is whether you think Personalis has earned that kind of premium yet.

Next Steps

If the mixed signals in this Personalis story leave you undecided, now is the time to review the full picture yourself, including 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Personalis stock?

If you only stop at Personalis, you might miss other stocks that fit your style even better. Use this moment to broaden your opportunity set with confidence.

• Target potential mispricings by scanning companies that screen as attractively valued through the screener containing 20 high quality undiscovered gems.
• Strengthen your downside protection by focusing on companies that feature in the 68 resilient stocks with low risk scores.
• Power up your watchlist with companies that combine financial resilience and solid fundamentals using the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.